Gilead CEO Daniel O'Day on acquisition of cancer drugmaker Immunomedics  CNBC TelevisionView Full coverage on Google News

Gilead Sciences Inc will acquire biotech company Immunomedics Inc for $21 billion, a move that will strengthen its cancer portfolio by gaining access to a promising drug, the two companies said in a joint statement on Sunday.Gilead Sciences Inc will acquire biotech company Immunomedics Inc for $21 billion, a move that will strengthen its cancer portfolio by gaining access to a promising drug, the two companies said in a joint statement on Sunday.

Gilead to buy cancer drugmaker Immunomedics for $21 billion | Reuters

(Bloomberg Opinion) -- Gilead Pharmaceuticals Inc. has faced the same problem for years: The drugmaker has a strong core business in its world-leading HIV franchise, but it hasn’t been able to consistently grow beyond that base the way it should. Against that backdrop, you'd think a more aggressive(Bloomberg Opinion) -- Gilead Pharmaceuticals Inc. has faced the same problem for years: The drugmaker has a strong core business in its world-leading HIV franchise, but it hasn’t been able to consistently grow beyond that base the way it should. Against that backdrop, you'd think a more aggressive

Gilead's $21 Billion Deal Splurge May End in Regret

Bloomberg - Are you a robot?

News, analysis and comment from the Financial Times, the worldʼs leading global business publication

Subscribe to read | Financial Times

Gilead in Advanced Talks for Immunomedics,  Bid More Than $20 Billion - BNN Bloomberg

A drugs company that has launched a treatment for Covid-19 is closing in on a $20 billion takeover of an American peer.Gilead Sciences is said to be nearing an acquisition of Immunomedics, aA drugs company that has launched a treatment for Covid-19 is closing in on a $20 billion takeover of an American peer.Gilead Sciences is said to be nearing an acquisition of Immunomedics, a

Shares of the cancer drug specialist Immunomedics more than doubled before the market opened Monday, a day after its sale to Gilead Sciences for $21 billion was announced. Shares of the cancer drug specialist Immunomedics more than doubled before the market opened Monday, a day after its sale to Gilead Sciences for $21 billion was announced.

Gilead Sciences Buying Immunomedics In $21 Billion Deal

Gilead Sciences Inc will acquire biopharmaceutical company Immunomedics Inc for US$21 billion in a deal that would further expand Gilead's ...Gilead Sciences Inc will acquire biopharmaceutical company Immunomedics Inc for US$21 billion in a deal that would further expand Gilead's ...

Gilead nears deal to buy Immunomedics for more than US$20 billion: Report - CNA

Gilead saw an chance to get a foundational asset in solid tumor oncology, while Immunomedics saw a chance to cap off a dramatic turnaround.Gilead saw an chance to get a foundational asset in solid tumor oncology, while Immunomedics saw a chance to cap off a dramatic turnaround.

Inside Gilead’s $21 billion purchase of Immunomedics

404 Not Found

The deal, which will expand Gilead’s oncology portfolio, might get announced tomorrow if not sooner, inform reports

Gilead may soon buy Immunomedics in deal over $20 billion - Express Pharma

Are Biotech Penny Stocks On Your List After Gilead & Immunomedics Ink A $21B Deal?

4 Penny Stocks To Watch After Gilead & Immunomedics' $21B Deal

A big premium for cancer drug company Immunomedics could pay off, but shareholders of slumping Gilead might be in no rush to act that way.A big premium for cancer drug company Immunomedics could pay off, but shareholders of slumping Gilead might be in no rush to act that way.

Gilead’s $20 Billion Gamble - WSJ

The big purchase adds one of the year's most highly anticipated new cancer therapies to Gilead's product line.The big purchase adds one of the year's most highly anticipated new cancer therapies to Gilead's product line.

Gilead Sciences to Acquire Immunomedics for $21 Billion in Cash | The Motley Fool

Discussions between Gilead Sciences and Immunomedics were initially centered around a partnership before shifting to a full-fledged takeover negotiation.Discussions between Gilead Sciences and Immunomedics were initially centered around a partnership before shifting to a full-fledged takeover negotiation.

Gilead nears deal to buy Immunomedics for more than $20 billion: Report

Gilead Sciences Inc will acquire biopharmaceutical company Immunomedics Inc for $21 billion in a deal that would further expand Gilead's portfolio of cancer treatments, the companies said on Sunday in a statement.Gilead Sciences Inc will acquire biopharmaceutical company Immunomedics Inc for $21 billion in a deal that would further expand Gilead's portfolio of cancer treatments, the companies said on Sunday in a statement.

Gilead Sciences, Inc. (Nasdaq: GILD) and Immunomedics (Nasdaq: IMMU) announced today that the companies have entered into a definitive agreement pursuGilead Sciences, Inc. (Nasdaq: GILD) and Immunomedics (Nasdaq: IMMU) announced today that the companies have entered into a definitive agreement pursu

Gilead Sciences to Acquire Immunomedics | Business Wire

Gilead Sciences Inc is nearing a deal to buy biopharmaceutical company Immunomedics Inc for more than $20 billion in a deal that would further expand Gilead's portfolio of cancer treatments, the Wall Street Journal reported on Saturday.Gilead Sciences Inc is nearing a deal to buy biopharmaceutical company Immunomedics Inc for more than $20 billion in a deal that would further expand Gilead's portfolio of cancer treatments, the Wall Street Journal reported on Saturday.

Gilead nears deal to buy Immunomedics for more than $20 billion, WSJ reports | Article [AMP] | Reuters

Biotech drugmaker has a market value of roughly $10 billionBiotech drugmaker has a market value of roughly $10 billion

Gilead nears deal to buy Immunomedics for more than $20 billion

Here’s what you need to know to navigate the markets today.Here’s what you need to know to navigate the markets today.

News Updates: Oracle Chosen as Winner in TikTok Sale | Barron's

The drugmaker is once again overpaying for something it needs — growth and diversification. Buying Immunomedics won’t completely solve its problems.

Gilead's $21 Billion Deal Splurge May End in Regret

Gilead Sciences Inc is nearing a deal to buy biopharmaceutical company Immunomedics Inc for more than $20 billion in a deal that would further expand Gilead’s portfolio of cancer treatments, the Wall Street Journal reported on Saturday. A deal for Immunomedics, whose cancer therapy Trodelvy is FDA-approved as a third-line…Gilead Sciences Inc is nearing a deal to buy biopharmaceutical company Immunomedics Inc for more than $20 billion in a deal that would further expand Gilead’s portfolio of cancer treatments, the Wall Street Journal reported on Saturday. A deal for Immunomedics, whose cancer therapy Trodelvy is FDA-approved as a third-line…

Gilead nears $20 billion deal to buy Immunomedics -- WSJ | Cyprus Mail

Gilead nears $20 billion deal to buy Immunomedics — WSJ – Cyprus Mail

GILEAD Sciences Inc is nearing a deal to buy biopharmaceutical company Immunomedics Inc for more than $20 billion in a deal that would further expand Gilead's portfolio of cancer treatments, the Wall Street Journal reported on Saturday.GILEAD Sciences Inc is nearing a deal to buy biopharmaceutical company Immunomedics Inc for more than $20 billion in a deal that would further expand Gilead's portfolio of cancer treatments, the Wall Street Journal reported on Saturday.

Gilead nears deal to buy Immunomedics for more than USD$20b | The Star

Gilead Sciences Inc. is nearing a deal to buy biotech Immunomedics Inc. and its prized breast-cancer drug for more than $20 billion.Gilead Sciences Inc. is nearing a deal to buy biotech Immunomedics Inc. and its prized breast-cancer drug for more than $20 billion.

Gilead near deal to buy Immunomedics for more than $20 billion - MarketWatch

403 Forbidden

Breaking News, Latest News and Current News from OANN.com. Breaking news and video. Latest Current News: U.S., World, Entertainment, Health, Business, Technology, Politics, Sports.

Gilead nears deal to buy Immunomedics for more than $20 billion – WSJ | One America News Network